Advances in Therapy · 2020 · 43 citations · 12 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmunotherapy SafetyLung CancerLung Cancer PharmacotherapyPericardial Disease In OncologyChemotherapy-associated Pericardial ToxicityImmunotherapy-related Pericardial ToxicityNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPericardial Involvement In CancerSquamous Cell Carcinoma HistologyThird-line Treatment
INTRODUCTION: Cardiovascular toxicity of immunotherapy represents an underreported but potentially fatal side effect. A relatively high incidence of pericardial disease has been noticed in patients with non-small cell lung cancer (NSCLC). METHODS: We retrospectively analyzed a population of patients with advanced NSCLC receiving immune checkpoint inhibitors (ICIs) looking for the presence of pericardial effusion at baseline or during treatment. The study population was compared with a control group treated with chemotherapy. All patients were checked for the presence of concomitant pleural effusion. RESULTS: We identify 60 patients (36 male/24 female, median age 70 years [range 43-81]). Prevalent histology was adenocarcinoma (65%) followed by squamous cell carcinoma (28%) and large cell or not otherwise specified (NOS) carcinoma (7%). Treatment consisted of nivolumab 3 mg/kg every 14 days (52 cases; 45 as second-line and 7 as third-line treatment) or pembrolizumab 200 mg (8 cases; all first-line treatment) for a total of 302 cycles delivered. Four out of 60 patients (6.7%) developed pericardial effusion during treatment, in two cases (3.3%) without concomitant pleural effusion, compared to 2 out of 60 (3.3%) in the control group in one case without concomitant pleural effusion (1.6%). Median time of onset was 40 days. Myocarditis was not observed. CONCLUSION: Our findings confirm pericardial effusion as a relatively frequent side effect of immunotherapy in NSCLC. Clinicians should be aware of this specific toxicity in patients with metastatic NSCLC receiving immunotherapy and refer to a cardiologist for a multidisciplinary approach.
12
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. Johnson, Justin M. Balko, Margaret Compton et al. · New England Journal of Medicine · 2016 · 2.3K citations · Full text
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Hiroyuki Nishimura, Taku Okazaki, Yoshimasa Tanaka et al. · Science · 2001 · 1.9K citations
Life Sciences, Cardiology, Pathology +11